Abstract: Chromoblastomycosis is a chronic, granulomatous, suppurative mycosis of the skin and subcutaneous tissue caused by traumatic inoculation of dematiaceous fungi of the family Herpotrichiellaceae. The species Fonsecaea pedrosoi and Cladophialophora carrionii are prevalent in regions where the disease is endemic. Chromoblastomycosis lesions are polymorphous: verrucous, nodular, tumoral, plaque-like, and atrophic. It is an occupational disease that predominates in tropical and subtropical regions, but there have been several reports of cases in temperate regions. The disease mainly affects current or former farm workers, mostly males, and often leaving disabling sequelae. This mycosis is still a therapeutic challenge due to frequent recurrence of lesions. Patients with extensive lesions require a combination of pharmacological and physical therapies. The article provides an update of epidemiological, clinical, diagnostic, and therapeutic features.
INTRODUCTION
The World Health Organization (WHO) keeps a long list of neglected diseases, which is defined as endemic tropical and subtropical diseases in low-income populations that cause thousands of deaths a year. The list includes diseases caused by infectious and parasitic agents (fungi, viruses, bacteria, protozoans, and helminths). In Brazil, the neglected diseases include deep mycoses such as CMB, paracoccidioidomycosis, Jorge Lobo's disease, mycetomas, sporotrichosis, and others. 5 
ETIOLOGY
The etiological agents of CBM belong to the order Chaeto- 26 The most prevalent species (90%) is F. pedrosoi. 19, 20, [27] [28] [29] [30] Cases of CBM caused by Exophiala jeanselmei and Exophiala spinifera have been reported in the literature. [31] [32] [33] [34] In Panama (2007), there is a report of CBM caused by Chaetomium funicola. 35 In the tissues, the fungi display a micromorphology of round/oval, brownish, thick-walled cells 4-12 microns in diameter, which multiply by septation in two distinct planes, called muriform (sclerotic) bodies (cells) or Medlar's bodies, representing the invasive form. The term muriform is preferred to sclerotic, according to
Matsumoto. 36 The melanin from the dematiaceous fungi is formed by the polymer dihydroxy naphthalene (DHN), which forms the melanin complex by interacting with proteins, lipids, and carbohydrates from the cell wall and represents an important factor in the virulence of these fungi.
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EPIDEMIOLOGY CBM is a cosmopolitan disease, with the highest prevalence in tropical and subtropical regions between 30° latitude North and 30° latitude South. 38 The largest focus of CBM in the world is in Madagascar, Africa. 39 However, the mycosis displays variable incidence in South America, Central America, North America, Asia, and
Europe. Among the countries with temperate climates, there have been reports in Russia, Canada, Finland, Czech Republic, Romania, and Poland, in addition to high incidence in Japan. 17, [40] [41] [42] [43] [44] [45] In Venezuela, C. carrionii predominates in the arid states of Lara and Falcón, while F. pedrosoi predominates in humid areas. 20, 23, 27, 28, 46 The mycosis occurs in most states of Brazil, the country with the second largest case series, and where the state of Pará has the highest prevalence. 23, 28, 30, 47, 48 Current or former agricultural workers, miners, and woodsmen, predominantly males 20 to 60 years of age, account for 90% of the cases. There is no ethnic predilection. In Japan, the lesions predominate on the upper limbs, face, and neck. 44, 45 There is no record of direct human-to-human or animal-to-human transmission. form, diffuse cutaneous form, on the scapular region, two cases on the axillae, on the abdomen, on the cornea, on the conjunctiva simulating melanoma, on the auricular region, and as a phagedenic ulcer on the face. 43, [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] Oral CBM was reported by Fatemi et al. 77 Cases of extracutaneous CBM are rare, but hematogenous, lymphatic, or contiguous dissemination of the fungus has been known to metastasize to lymph nodes and lungs and produce osteolytic lesions underlying the skin lesion. [78] [79] [80] There are reports of fatal cases of brain abscesses caused by F. monophora and F. pugnacius. There is an interesting report of detection of CBM agents using Ziehl-Neelsen and Wade-Fite staining, a useful approach in cases that are difficult with HE staining. 96 Our study used Fite-Faraco staining and showed the dimorphism of the fungus -presence of muriform bodies associated with dematiaceous septated hyphae 
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PATHOGENESIS
104
There was a recent promising description of photodynamic therapy in CBM. 105, 106 Hu et al. used oral terbinafine in combination with photodynamic therapy with 5-aminolevulinic acid in a case of CBM, with apparent clinical improvement in less than a year and no recurrence. 107 Mohs micrographic surgery has been used to treat a variety of skin neoplasms with excellent results. The technique was used successfully to treat a localized cutaneous CMB lesion, with no recurrence of the lesion after a year of follow-up. 108 The antifungals that have shown the greatest efficacy are itraconazole (200-400mg/day) and terbinafine (500-1000mg/day) for at least 6-12 months, preferably at higher doses if tolerated. [109] [110] [111] [112] [113] Both drugs showed high in vitro activity against the causative agents of CBM. 114, 115 Pulse therapy with itraconazole was reported (400mg/ day for 7 days/month) and proved more economical and effective and associated with better treatment adherence. 116, 117 In addition, the combination of an azole (itraconazole) and an allylamine (terbinafine) with different targets and synergistic effect has been used. Negroni et al. 122 assessed six CBM patients that were resistant to conventional antifungal therapies and administered 800mg/ day of posaconazole, with clinical success in five of the six patients.
Posaconazole was well tolerated during long-term administration.
122
Oral voriconazole was tested in some cases of treatment in resistant forms of CBM. 106, 120, 121 Good clinical results were achieved with this drug, but adverse effects like visual disturbances and photosensitive skin reactions were observed.
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Among the other antifungals, ketoconazole is not recommended for prolonged treatment, because high doses are associated with toxicity. Fluconazole is also contraindicated, since in vitro studies have shown its limited activity against dematiaceous fungi.
115
Fluorocytosine (converted into 5-fluorouracil in fungal cells) shows some degree of efficacy but is associated with high risk of development of resistance, besides being hepatotoxic and myelotoxic. 123 With the emergence of more recent antifungals, the drug is now rarely used except in selected resistant cases. The combination of itraconazole and fluorocytosine has only been evaluated in a small number of patients but has proven very effective even in severe forms of subcutaneous mycoses. 125 The pharmacological data showed an additive effect against fungi, where fluorocytosine causes suppression of the yeast's DNA synthesis and itraconazole acts on the cell membrane, inhibiting the synthesis of ergosterol. 126 Despite an insufficient number of cases for a detailed comparison, combination therapy with these two drugs can be an option in severe cases of CBM. 
